HSP90AA1 and cancer: There are ongoing clinical trials investigating the combination of BGT226 (or other PI3K/mTOR inhibitors) with HSP90 inhibitors like STA9090 in other cancers, but data on safety, efficacy, and optimal dosing regimens are still emerging.